Latest From ORIG3N Inc.
While US regulators have ramped up the number of authorizations they’ve granted to companies on an emergency basis in response to the COVID-19 crisis, they really kicked things into high gear in just the past few days. On 10 April the agency issued a record number of EUAs in response to the pandemic.
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.
Bioventures seeking IPOs in the South Korean stock market are having a tough time due to waning interest from investors. A surge in such offerings this year, coupled with the usual IPO rush seen at the end of each year, have resulted in several biotech companies withdrawing plans or raising funds short of initial targets.
Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- ORIG3N Inc.
- Senior Management
Robin Y Smith, CEO
Kate Blanchard, COO
Marcie Glicksman, PhD, VP, Biology
James Lovgren, CBO
Jamie Metzl, PhD, Chief Strategy Officer
Michael Fang, MD, Chief Medical Officer
- Contact Info